MY192464A - Sustained-release preparation of cilostazol - Google Patents

Sustained-release preparation of cilostazol

Info

Publication number
MY192464A
MY192464A MYPI2019004733A MYPI2019004733A MY192464A MY 192464 A MY192464 A MY 192464A MY PI2019004733 A MYPI2019004733 A MY PI2019004733A MY PI2019004733 A MYPI2019004733 A MY PI2019004733A MY 192464 A MY192464 A MY 192464A
Authority
MY
Malaysia
Prior art keywords
cilostazol
sustained
release preparation
release
pharmaceutically acceptable
Prior art date
Application number
MYPI2019004733A
Other languages
English (en)
Inventor
Bo Kyung Kim
Kwang-Ho Cho
Youn Woong Choi
Sang Min Cho
Original Assignee
Korea United Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea United Pharm Inc filed Critical Korea United Pharm Inc
Publication of MY192464A publication Critical patent/MY192464A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2019004733A 2018-08-17 2019-04-09 Sustained-release preparation of cilostazol MY192464A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180096354A KR102138253B1 (ko) 2018-08-17 2018-08-17 실로스타졸 서방성 제제
PCT/KR2019/004224 WO2020036284A1 (ko) 2018-08-17 2019-04-09 실로스타졸 서방성 제제

Publications (1)

Publication Number Publication Date
MY192464A true MY192464A (en) 2022-08-22

Family

ID=69524815

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019004733A MY192464A (en) 2018-08-17 2019-04-09 Sustained-release preparation of cilostazol

Country Status (3)

Country Link
KR (1) KR102138253B1 (ko)
MY (1) MY192464A (ko)
WO (1) WO2020036284A1 (ko)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070024254A (ko) * 2005-08-26 2007-03-02 한국오츠카제약 주식회사 실로스타졸 함유 서방정
US20110165236A1 (en) 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
KR20150064227A (ko) * 2007-10-19 2015-06-10 오츠카 세이야쿠 가부시키가이샤 매트릭스형 의약 고형 제제
CN102365083A (zh) * 2009-03-18 2012-02-29 赢创罗姆有限公司 采用包含聚合物混合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
KR101068475B1 (ko) * 2009-12-29 2011-09-28 환인제약 주식회사 실로스타졸을 포함하는 서방성 제제 및 이의 제조방법
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
WO2020036284A1 (ko) 2020-02-20
KR20200020542A (ko) 2020-02-26
KR102138253B1 (ko) 2020-07-29

Similar Documents

Publication Publication Date Title
PH12019502325A1 (en) Sustained release delivery systems comprising traceless linkers
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
PE20160180A1 (es) Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos.
WO2017037593A3 (zh) 用于减少局部脂肪的医药组成物及其用途
PH12020551263A1 (en) Sustained release formulations of bempedoic acid
MY187358A (en) Modified release orally administered amino acid formulations
MX2021007161A (es) Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia.
WO2019108021A3 (ko) 토파시티닙을 포함하는 약제학적 조성물
BR112017012566A2 (pt) formulações farmacêuticas de inibidores de cinases relacionadas à tropomiosina (trk)
MX2019001032A (es) Formulacion que tiene caracteristicas mejoradas de liberacion de farmacos ph dependientes, que contienen esomeprazol o una de sus sales farmaceuticas aceptable.
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
SG11201909590XA (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
MX2018012224A (es) Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas.
PH12019500919A1 (en) Esomeprazole~containing complex capsule and preparation method therefor
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MY192464A (en) Sustained-release preparation of cilostazol
EA202190561A1 (ru) Препараты ag10
MX2019004375A (es) Inhibidores de bromodominios.
JOP20170197B1 (ar) الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول
PH12020500228A1 (en) Pharmacutical composition comprising remogliflozin and antidiabetic agent
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
MX2019005005A (es) Tableta de liberacion extendida que comprende un farmaco de perdida de peso.
MX2021011795A (es) Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble.
EA202191603A1 (ru) Фармацевтическая композиция